董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Strobeck | 男 | Director,President and Chief Executive Officer | 54 | 189.55万美元 | 53.55 | 2025-11-17 |
| Joan Lau | 女 | Director | 54 | 11.69万美元 | 13.81 | 2025-11-17 |
| Joseph H. Dawson | 男 | Director | 60 | 4.38万美元 | 未持股 | 2025-11-17 |
| John G. Cooper | 男 | Director | 66 | 12.60万美元 | 16.08 | 2025-11-17 |
| Allen R. Nissenson | 男 | Director | 78 | 11.60万美元 | 15.24 | 2025-11-17 |
| Mark H. Ravich | 男 | Director | 72 | 11.35万美元 | 16.64 | 2025-11-17 |
| Robert S. Radie | 男 | Chairman | 61 | 13.85万美元 | 15.38 | 2025-11-17 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark Strobeck | 男 | Director,President and Chief Executive Officer | 54 | 189.55万美元 | 53.55 | 2025-11-17 |
| Megan Timmins | 女 | Executive Vice President, Chief Legal Officer and Secretary | 52 | 97.82万美元 | 20.25 | 2025-11-17 |
| Jesse Neri | 男 | Senior Vice President and Chief Financial Officer | 47 | 82.88万美元 | 8.08 | 2025-11-17 |
| Timothy Chole | 男 | Senior Vice President and Chief Commercial Officer | 51 | 未披露 | 未持股 | 2025-11-17 |
| Heather Hunter | 女 | Senior Vice President and Chief Operating Officer | 46 | 未披露 | 未持股 | 2025-11-17 |
董事简历
中英对照 | 中文 | 英文- Mark Strobeck
-
Mark Strobeck自2023年6月起担任Windtree Therapeutics, Inc.董事会成员，并担任审计和薪酬委员会成员。自2022年7月起，斯特罗贝克博士还担任生物制药公司Rockwell Medical, Inc.的总裁兼首席执行官和董事会成员。斯特罗贝克博士曾于2021年5月至2022年6月担任生命科学投资银行Aquilo Partners，LP的董事总经理。他曾于2020年5月至2020年12月担任制药公司Assertio Holdings, Inc.执行副总裁兼首席运营官。在此之前，斯特罗贝克博士于2015年9月与Assertio Holdings公司于2020年5月合并后担任制药公司Zyla Life Sciences的执行副总裁兼首席运营官，并曾于2014年1月至2015年9月担任Zyla的首席商务官。在受雇于Zyla之前，他曾在2012年6月至2013年12月期间担任Zyla的顾问。2012年1月至2013年12月，他担任Corridor Pharmaceuticals，Inc.的总裁兼首席执行官和董事。Corridor Pharmaceuticals，Inc.是一家制药公司，于2014年被阿斯利康收购。2010年12月至2011年10月，斯特罗贝克博士担任Topaz Pharmaceuticals Inc.的首席商务官，这是一家专业制药公司，于2011年第四季度被赛诺菲巴斯德收购。2010年6月至2010年11月和2011年10月至2012年1月，斯特罗贝克博士担任顾问。2008年1月至2010年5月，斯特罗贝克博士担任制药公司Trevena, Inc.的首席商务官。在加入Trevena之前，斯特罗贝克博士曾在制药公司葛兰素史克、风险投资公司SR One Limited和EuclidSR Partners，L.P担任管理职务。斯特罗贝克博士目前是Horse Power For Life的董事会成员，该公司是一家非营利组织，致力于提高被诊断患有癌症的人的生活质量，他自2012年以来一直担任该职位。斯特罗贝克博士于1993年在圣劳伦斯大学获得生物学学士学位，1999年在辛辛那提大学获得药理学和生物物理学博士学位，并于2001年在宾夕法尼亚大学医学院完成了心血管基因调控方面的博士后研究。
Mark Strobeck,has served as a member of Windtree Therapeutics, Inc. Board since June 2023 and also serves as a member of the Audit and Compensation Committees. Dr. Strobeck has also served as the President and CEO, and as a member of the board of directors, of Rockwell Medical, Inc., a biopharmaceutical company, since July 2022. Dr, Strobeck previously served as Managing Director of Aquilo Partners, LP, a life sciences investment bank, from May 2021 to June 2022. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company, from May 2020 to December 2020. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla's Chief Business Officer from January 2014 to September 2015. Before his employment at Zyla, he served as Zyla's advisor from June 2012 to December 2013. From January 2012 to December 2013, he served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University in 1993 and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati in 1999 and completed his post-doctoral fellowship in Cardiovascular Gene Regulation at the University of Pennsylvania School of Medicine in 2001. - Mark Strobeck自2023年6月起担任Windtree Therapeutics, Inc.董事会成员，并担任审计和薪酬委员会成员。自2022年7月起，斯特罗贝克博士还担任生物制药公司Rockwell Medical, Inc.的总裁兼首席执行官和董事会成员。斯特罗贝克博士曾于2021年5月至2022年6月担任生命科学投资银行Aquilo Partners，LP的董事总经理。他曾于2020年5月至2020年12月担任制药公司Assertio Holdings, Inc.执行副总裁兼首席运营官。在此之前，斯特罗贝克博士于2015年9月与Assertio Holdings公司于2020年5月合并后担任制药公司Zyla Life Sciences的执行副总裁兼首席运营官，并曾于2014年1月至2015年9月担任Zyla的首席商务官。在受雇于Zyla之前，他曾在2012年6月至2013年12月期间担任Zyla的顾问。2012年1月至2013年12月，他担任Corridor Pharmaceuticals，Inc.的总裁兼首席执行官和董事。Corridor Pharmaceuticals，Inc.是一家制药公司，于2014年被阿斯利康收购。2010年12月至2011年10月，斯特罗贝克博士担任Topaz Pharmaceuticals Inc.的首席商务官，这是一家专业制药公司，于2011年第四季度被赛诺菲巴斯德收购。2010年6月至2010年11月和2011年10月至2012年1月，斯特罗贝克博士担任顾问。2008年1月至2010年5月，斯特罗贝克博士担任制药公司Trevena, Inc.的首席商务官。在加入Trevena之前，斯特罗贝克博士曾在制药公司葛兰素史克、风险投资公司SR One Limited和EuclidSR Partners，L.P担任管理职务。斯特罗贝克博士目前是Horse Power For Life的董事会成员，该公司是一家非营利组织，致力于提高被诊断患有癌症的人的生活质量，他自2012年以来一直担任该职位。斯特罗贝克博士于1993年在圣劳伦斯大学获得生物学学士学位，1999年在辛辛那提大学获得药理学和生物物理学博士学位，并于2001年在宾夕法尼亚大学医学院完成了心血管基因调控方面的博士后研究。
- Mark Strobeck,has served as a member of Windtree Therapeutics, Inc. Board since June 2023 and also serves as a member of the Audit and Compensation Committees. Dr. Strobeck has also served as the President and CEO, and as a member of the board of directors, of Rockwell Medical, Inc., a biopharmaceutical company, since July 2022. Dr, Strobeck previously served as Managing Director of Aquilo Partners, LP, a life sciences investment bank, from May 2021 to June 2022. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company, from May 2020 to December 2020. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla's Chief Business Officer from January 2014 to September 2015. Before his employment at Zyla, he served as Zyla's advisor from June 2012 to December 2013. From January 2012 to December 2013, he served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University in 1993 and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati in 1999 and completed his post-doctoral fellowship in Cardiovascular Gene Regulation at the University of Pennsylvania School of Medicine in 2001.
- Joan Lau
-
刘琼，自2023年10月起担任董事。自2016年以来，Dr. Lau一直担任Spirovant Sciences Inc.（被收购前的前身为Talee Bio）的首席执行官，该公司专注于呼吸系统疾病基因疗法的发现和开发，由她创立。自2013年以来，Dr. Lau一直是Militia Hill Ventures的联合创始人和合伙人，该公司是一家创建和建立创新生命科学实体的公司。刘博士还担任布兰迪维因房地产信托（BDN）的受托人，该信托是一家上市、提供全方位服务的综合房地产公司，Universal Display Corporation是一家上市公司，自2024年3月起担任该公司的受托人，并担任私营公司RiboNova，Inc.的董事。她此前曾担任Renovacor, Inc.公司董事。刘博士也是费城管弦乐团和金梅尔中心公司以及宾夕法尼亚大学的受托人。Lau博士在费城大学沃顿商学院获得MBA学位，在辛辛那提大学医学院获得医学神经科学博士学位，在宾夕法尼亚大学获得生物工程BSE学位。
Joan Lau,has been a director since October 2023. Since 2016, Dr. Lau has served as Chief Executive Officer of Spirovant Sciences Inc. (formerly Talee Bio prior to its acquisition), a company focused on the discovery and development of gene therapies for respiratory diseases, which she founded. Since 2013, Dr. Lau has been co-founder and partner of Militia Hill Ventures, a firm that creates and builds innovative life science entities. Dr. Lau also serves as trustee of the Brandywine Realty Trust (BDN), a publicly-traded, full-service, integrated real estate company, Universal Display Corporation, a publicly traded company, since March 2024, and as a director of RiboNova, Inc., a private company. She previously served as a director of Renovacor, Inc. Dr. Lau is also a trustee of the Philadelphia Orchestra and Kimmel Center, Inc. and the University of Pennsylvania. Dr. Lau earned an MBA from the Wharton School at the University of Philadelphia, a PhD in Medical Neuroscience from the University of Cincinnati College of Medicine, and a BSE in Bioengineering from the University of Pennsylvania. - 刘琼，自2023年10月起担任董事。自2016年以来，Dr. Lau一直担任Spirovant Sciences Inc.（被收购前的前身为Talee Bio）的首席执行官，该公司专注于呼吸系统疾病基因疗法的发现和开发，由她创立。自2013年以来，Dr. Lau一直是Militia Hill Ventures的联合创始人和合伙人，该公司是一家创建和建立创新生命科学实体的公司。刘博士还担任布兰迪维因房地产信托（BDN）的受托人，该信托是一家上市、提供全方位服务的综合房地产公司，Universal Display Corporation是一家上市公司，自2024年3月起担任该公司的受托人，并担任私营公司RiboNova，Inc.的董事。她此前曾担任Renovacor, Inc.公司董事。刘博士也是费城管弦乐团和金梅尔中心公司以及宾夕法尼亚大学的受托人。Lau博士在费城大学沃顿商学院获得MBA学位，在辛辛那提大学医学院获得医学神经科学博士学位，在宾夕法尼亚大学获得生物工程BSE学位。
- Joan Lau,has been a director since October 2023. Since 2016, Dr. Lau has served as Chief Executive Officer of Spirovant Sciences Inc. (formerly Talee Bio prior to its acquisition), a company focused on the discovery and development of gene therapies for respiratory diseases, which she founded. Since 2013, Dr. Lau has been co-founder and partner of Militia Hill Ventures, a firm that creates and builds innovative life science entities. Dr. Lau also serves as trustee of the Brandywine Realty Trust (BDN), a publicly-traded, full-service, integrated real estate company, Universal Display Corporation, a publicly traded company, since March 2024, and as a director of RiboNova, Inc., a private company. She previously served as a director of Renovacor, Inc. Dr. Lau is also a trustee of the Philadelphia Orchestra and Kimmel Center, Inc. and the University of Pennsylvania. Dr. Lau earned an MBA from the Wharton School at the University of Philadelphia, a PhD in Medical Neuroscience from the University of Cincinnati College of Medicine, and a BSE in Bioengineering from the University of Pennsylvania.
- Joseph H. Dawson
-
Joseph H. Dawson，目前担任独立顾问。2013年5月至2025年6月任Nipro Medical Corporation北美区总裁。在此之前，Dawson先生曾担任Cordis Corporation的企业客户销售高级总监，该公司当时是强生的子公司。道森先生在圣约翰大学获得神经生物学理学学士学位。
Joseph H. Dawson,currently serves as an independent consultant. From May 2013 to June 2025, he served as President, North America of Nipro Medical Corporation. Prior to that, Mr. Dawson served as Senior Director of Corporate Account Sales for Cordis Corporation, then a subsidiary of Johnson & Johnson. Mr. Dawson earned his Bachelor of Science in Neurobiology from St. John's University. - Joseph H. Dawson，目前担任独立顾问。2013年5月至2025年6月任Nipro Medical Corporation北美区总裁。在此之前，Dawson先生曾担任Cordis Corporation的企业客户销售高级总监，该公司当时是强生的子公司。道森先生在圣约翰大学获得神经生物学理学学士学位。
- Joseph H. Dawson,currently serves as an independent consultant. From May 2013 to June 2025, he served as President, North America of Nipro Medical Corporation. Prior to that, Mr. Dawson served as Senior Director of Corporate Account Sales for Cordis Corporation, then a subsidiary of Johnson & Johnson. Mr. Dawson earned his Bachelor of Science in Neurobiology from St. John's University.
- John G. Cooper
-
John G. Cooper，他一直担任审计委员会的董事和主席（2017年9月以来）。他目前是JGC Advisors的负责人，为新兴生命科学公司提供企业发展和财务咨询服务，并担任IC Surgical， Inc.的战略顾问委员会成员。从2001年到2016年，他是Windtree Therapeutics Inc.（前身为Discovery Laboratories， Inc.）的高级执行官，这是一家上市的生物制药公司，也是第一家获得FDA批准的合成肽含表面活性剂，用于治疗患有呼吸窘迫综合征的早产儿。在Discovery Labs，他曾担任总裁、首席执行官兼董事会成员（2013年至2016年），总裁兼首席财务官（2010年至2013年），执行副总裁兼首席财务官（2002年至2010年），高级副总裁兼首席财务官（2001年至2002年）。此前，他曾担任Chrysalis International Corporation（为生物制药行业提供药物开发服务的上市公司）和DNX Corporation（公共生命科学公司，开拓用于异种移植和生物治疗开发的转基因技术）的高级副总裁兼首席财务官。此前，他曾担任ENI Diagnostics， Inc.一家公共生命科学公司（被Pharmacia AB收购）的财务主管，该公司开发并商业化了第二种fda批准的HIV血液诊断测试，以及CR Bard， Inc.（一家公共医疗设备公司）的财务分析师。他于1985年获得注册会计师证书，并获得Rider大学的商业学士学位。
John G. Cooper,has been a director and Chair of the Audit Committee since September 2017. Mr. Cooper is currently principal of JGC Advisors, providing corporate development and financial advisory services to emerging life science companies, and serves on the strategic advisory board of IC Surgical, Inc. From 2001 to 2016, Mr. Cooper was a senior executive for Windtree Therapeutics Inc. (formerly Discovery Laboratories, Inc.), a publicly traded bio pharmaceutical company and the first to receive FDA approval for a synthetic peptide-containing surfactant to address premature infants with respiratory distress syndrome. At Discovery Labs, Mr. Cooper served as president, chief executive officer and a member of the board of directors from 2013 to 2016, president and chief financial officer from 2010 to 2013, executive vice president and chief financial officer from 2002 to 2010 and senior vice president and chief financial officer from 2001 to 2002. Previously, Mr. Cooper served as senior vice president and chief financial officer at Chrysalis International Corporation, a public company providing drug development services to the biopharmaceutical industry, and DNX Corporation, a public life sciences company pioneering transgenic technology for xenotransplantation and biotherapeutic development. Previously, Mr. Cooper served as a financial executive at ENI Diagnostics, Inc., a public life sciences company (acquired by Pharmacia AB) that developed and commercialized the second FDA-approved blood diagnostic test for HIV and a financial analyst at CR Bard, Inc., a public medical device company. Mr. Cooper earned a certified public accountant credential in 1985 and his B.S. in Commerce from Rider University. - John G. Cooper，他一直担任审计委员会的董事和主席（2017年9月以来）。他目前是JGC Advisors的负责人，为新兴生命科学公司提供企业发展和财务咨询服务，并担任IC Surgical， Inc.的战略顾问委员会成员。从2001年到2016年，他是Windtree Therapeutics Inc.（前身为Discovery Laboratories， Inc.）的高级执行官，这是一家上市的生物制药公司，也是第一家获得FDA批准的合成肽含表面活性剂，用于治疗患有呼吸窘迫综合征的早产儿。在Discovery Labs，他曾担任总裁、首席执行官兼董事会成员（2013年至2016年），总裁兼首席财务官（2010年至2013年），执行副总裁兼首席财务官（2002年至2010年），高级副总裁兼首席财务官（2001年至2002年）。此前，他曾担任Chrysalis International Corporation（为生物制药行业提供药物开发服务的上市公司）和DNX Corporation（公共生命科学公司，开拓用于异种移植和生物治疗开发的转基因技术）的高级副总裁兼首席财务官。此前，他曾担任ENI Diagnostics， Inc.一家公共生命科学公司（被Pharmacia AB收购）的财务主管，该公司开发并商业化了第二种fda批准的HIV血液诊断测试，以及CR Bard， Inc.（一家公共医疗设备公司）的财务分析师。他于1985年获得注册会计师证书，并获得Rider大学的商业学士学位。
- John G. Cooper,has been a director and Chair of the Audit Committee since September 2017. Mr. Cooper is currently principal of JGC Advisors, providing corporate development and financial advisory services to emerging life science companies, and serves on the strategic advisory board of IC Surgical, Inc. From 2001 to 2016, Mr. Cooper was a senior executive for Windtree Therapeutics Inc. (formerly Discovery Laboratories, Inc.), a publicly traded bio pharmaceutical company and the first to receive FDA approval for a synthetic peptide-containing surfactant to address premature infants with respiratory distress syndrome. At Discovery Labs, Mr. Cooper served as president, chief executive officer and a member of the board of directors from 2013 to 2016, president and chief financial officer from 2010 to 2013, executive vice president and chief financial officer from 2002 to 2010 and senior vice president and chief financial officer from 2001 to 2002. Previously, Mr. Cooper served as senior vice president and chief financial officer at Chrysalis International Corporation, a public company providing drug development services to the biopharmaceutical industry, and DNX Corporation, a public life sciences company pioneering transgenic technology for xenotransplantation and biotherapeutic development. Previously, Mr. Cooper served as a financial executive at ENI Diagnostics, Inc., a public life sciences company (acquired by Pharmacia AB) that developed and commercialized the second FDA-approved blood diagnostic test for HIV and a financial analyst at CR Bard, Inc., a public medical device company. Mr. Cooper earned a certified public accountant credential in 1985 and his B.S. in Commerce from Rider University.
- Allen R. Nissenson
-
Allen R. Nissenson，2008年8月成为担任医疗总监。他是加州大学洛杉矶分校医学院医学荣誉退休教授，1977-2008年在该校担任透析项目主管，2005-2008年担任副院长。2005-2007年担任南加利福尼亚End-Stage Renal Disease Network总裁。2001-2007年期间担任National Anemia Action Council主席。1999-2001年担任Renal Physicians Association主席。
Allen R. Nissenson has served as a member of Elicio's Board of Directors since June 2023 and previously served as a member of Angion's Board of Directors from January 2020 until the Merger. Dr. Nissenson completed serving as the Emeritus Chief Medical Officer of DaVita Kidney Care in January 2022, where he had served since January 2020 and where he previously served as Chief Medical Officer from August 2008 to January 2020. Dr. Nissenson is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at UCLA, where he has served since August 2008, and where he previously served as Director of the Dialysis Program from July 1977 to August 2008 and Associate Dean from July 2005 to August 2008. Dr. Nissenson is also currently on the board of directors of Rockwell Medical, Inc., a public biopharmaceutical company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products for dialysis providers, which he joined in June 2020, Diality, Inc., a private technology development company, and Innocura Nephology, Inc., a privately held company supporting a national group of nephrologists. Dr. Nissenson is a past chair of Kidney Care Partners and past co chair of the Kidney Care Quality Alliance. Dr. Nissenson is a former president of the Renal Physicians Association ("RPA") and current member of the RPA's Government Affairs Committee. Dr. Nissenson previously served as president of the Southern California End Stage Renal Disease Network, as well as the chair of its Medical Review Board. Dr. Nissenson served as a Robert Wood Johnson Health Policy Fellow of the National Academy of Medicine from 1994 to 1995 and worked in the office of the late Senator Paul Wellstone. Dr. Nissenson has an M.D. from Northwestern University Medical School and is the recipient of various awards, including the President's Award of the National Kidney Foundation, the Lifetime Achievement Award in Hemodialysis, the American Association of Kidney Patients' ("AAKP") Medal of Excellence Award and, in 2017, the RPA Distinguished Nephrology Service Award. - Allen R. Nissenson，2008年8月成为担任医疗总监。他是加州大学洛杉矶分校医学院医学荣誉退休教授，1977-2008年在该校担任透析项目主管，2005-2008年担任副院长。2005-2007年担任南加利福尼亚End-Stage Renal Disease Network总裁。2001-2007年期间担任National Anemia Action Council主席。1999-2001年担任Renal Physicians Association主席。
- Allen R. Nissenson has served as a member of Elicio's Board of Directors since June 2023 and previously served as a member of Angion's Board of Directors from January 2020 until the Merger. Dr. Nissenson completed serving as the Emeritus Chief Medical Officer of DaVita Kidney Care in January 2022, where he had served since January 2020 and where he previously served as Chief Medical Officer from August 2008 to January 2020. Dr. Nissenson is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at UCLA, where he has served since August 2008, and where he previously served as Director of the Dialysis Program from July 1977 to August 2008 and Associate Dean from July 2005 to August 2008. Dr. Nissenson is also currently on the board of directors of Rockwell Medical, Inc., a public biopharmaceutical company that develops, manufactures, commercializes and distributes a portfolio of hemodialysis products for dialysis providers, which he joined in June 2020, Diality, Inc., a private technology development company, and Innocura Nephology, Inc., a privately held company supporting a national group of nephrologists. Dr. Nissenson is a past chair of Kidney Care Partners and past co chair of the Kidney Care Quality Alliance. Dr. Nissenson is a former president of the Renal Physicians Association ("RPA") and current member of the RPA's Government Affairs Committee. Dr. Nissenson previously served as president of the Southern California End Stage Renal Disease Network, as well as the chair of its Medical Review Board. Dr. Nissenson served as a Robert Wood Johnson Health Policy Fellow of the National Academy of Medicine from 1994 to 1995 and worked in the office of the late Senator Paul Wellstone. Dr. Nissenson has an M.D. from Northwestern University Medical School and is the recipient of various awards, including the President's Award of the National Kidney Foundation, the Lifetime Achievement Award in Hemodialysis, the American Association of Kidney Patients' ("AAKP") Medal of Excellence Award and, in 2017, the RPA Distinguished Nephrology Service Award.
- Mark H. Ravich
-
Mark H. Ravich，他于2013年2月被任命为公司的董事。他的职业生涯始于1975年担任Citibank公司（位于纽约）的会计职员，在那里他为国家房地产开发商提供房地产建设贷款。从1978年离开Citibank公司到1990年，他曾担任商业地产的开发人员，在那里他参与各类商业、工业、办公、多家族房地产项目的开发、金融、建筑、销售、租赁和管理的各个方面。从1990年到1998年初该公司被卖给纽约零售商，他曾担任Universal International公司（批发零售公司）的首席执行官和董事会成员，并领导公司证券的公开发行。从1998年到现在，他担任Tri-Star Management公司（商业地产管理和联合公司）的创始人兼所有者。他也积极参与许多私人股本和风险资本投资。他目前任职于MR Instruments公司和Dilon Technologies公司的董事会，也是Scidera公司的董事会顾问，以及各种房地产实体的总经理。他以优异成绩毕业于Pennsylvania大学的沃顿商学院，并获得工程学士学位，以及工商管理硕士学位（主修金融）。
Mark H. Ravich,has been a director since June 2017. Mr. Ravich currently serves as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. From October 2010 through December 2022, Mr. Ravich served as a director of Dilon Technologies, Inc., a designer and manufacturer of medical imaging solutions. In addition, from February 2019 to March 2023, Mr. Ravich served as a director of BioVentrix Inc., a manufacturer of devices to improve and expand the treatments available for congestive heart failure. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International, Inc., a wholesale retail company, where he also led its IPO. From February 2013 to 2018, Mr. Ravich served as a director of Orchard Paper Products Company, a national supplier of high quality consumer tissue products, as well as chairman of its governance committee and as a member of its audit committee. From June 2004 to 2018, Mr. Ravich served as a director of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency coils. From 1978 to 1990, Mr. Ravich was a developer of commercial real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also currently serves as a board advisor to Scidera Inc., a provider of clinical laboratory testing services, and is the chief manager of various real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a B.S. and an M.B.A. degree with a major in finance. - Mark H. Ravich，他于2013年2月被任命为公司的董事。他的职业生涯始于1975年担任Citibank公司（位于纽约）的会计职员，在那里他为国家房地产开发商提供房地产建设贷款。从1978年离开Citibank公司到1990年，他曾担任商业地产的开发人员，在那里他参与各类商业、工业、办公、多家族房地产项目的开发、金融、建筑、销售、租赁和管理的各个方面。从1990年到1998年初该公司被卖给纽约零售商，他曾担任Universal International公司（批发零售公司）的首席执行官和董事会成员，并领导公司证券的公开发行。从1998年到现在，他担任Tri-Star Management公司（商业地产管理和联合公司）的创始人兼所有者。他也积极参与许多私人股本和风险资本投资。他目前任职于MR Instruments公司和Dilon Technologies公司的董事会，也是Scidera公司的董事会顾问，以及各种房地产实体的总经理。他以优异成绩毕业于Pennsylvania大学的沃顿商学院，并获得工程学士学位，以及工商管理硕士学位（主修金融）。
- Mark H. Ravich,has been a director since June 2017. Mr. Ravich currently serves as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded in 1998. From October 2010 through December 2022, Mr. Ravich served as a director of Dilon Technologies, Inc., a designer and manufacturer of medical imaging solutions. In addition, from February 2019 to March 2023, Mr. Ravich served as a director of BioVentrix Inc., a manufacturer of devices to improve and expand the treatments available for congestive heart failure. Previously, from 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International, Inc., a wholesale retail company, where he also led its IPO. From February 2013 to 2018, Mr. Ravich served as a director of Orchard Paper Products Company, a national supplier of high quality consumer tissue products, as well as chairman of its governance committee and as a member of its audit committee. From June 2004 to 2018, Mr. Ravich served as a director of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency coils. From 1978 to 1990, Mr. Ravich was a developer of commercial real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also currently serves as a board advisor to Scidera Inc., a provider of clinical laboratory testing services, and is the chief manager of various real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a B.S. and an M.B.A. degree with a major in finance.
- Robert S. Radie
-
Robert S. Radie，他是公司的总裁兼首席执行官和董事会成员，并自2012年3月担任这些职位。2010年11月至2011年10月，他曾担任 Topaz Pharmaceuticals 的总裁和首席执行官。从2009年3月至2010年11月，从2008年12月至2009年3月担任Transmolecular的顾问后，他担任Transmolecular公司（生物技术公司，开发的癌症诊断和治疗产品）的总裁兼首席执行官。2008年9月至2008年12月他失业了。从2007年9月至2008年9月他担任Prestwick制药公司（一家专业制药公司）的首席商务官。加入 Prestwick之前，他担任一些制药和生物技术公司的中高层管理职位，包括Morphotek公司，Vicuron制药公司和礼来公司，并为Affinium制药有限公司的董事从2012年7月至2014年3月，此时大多数Affinium的资产被第三方收购了。他还担任Horse Power For Life的董事，2007年以来他就担任此职位。他获得波士顿学院化学学士学位。
Robert S. Radie,has been a director since March 2020 and Chairman of the Board since April 2022. Mr. Radie has served as Chief Executive Officer and Chairman of the board of directors of Neuraptive Therapeutics, Inc., a private, clinical stage company focused on improving outcomes in traumatic peripheral nerve injury, since June 2020. He previously served as President and Chief Executive Officer and a member of the board of directors of Zyla Life Sciences, a life sciences company, from March 2012 to October 2019. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie has been a member of the board of directors ValSource Inc. since October 2020 and has also served as a director of Orcosa Inc since Jan of 2024. He previously served as a member of the board of directors of Paratek Pharmaceuticals from November 2014 to September 2023,Veloxis Pharmaceuticals A/S from June 2016 to February 2020 and Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014. He also served as a Director for Life Science PA, an industry advocacy group in Pennsylvania. Previously, he served as a director of Horse Power for Life, a nonprofit organization of to improving the quality of life for individuals diagnosed with cancer from 2006 through 2024. Mr. Radie received his B.S. in Chemistry from Boston College. - Robert S. Radie，他是公司的总裁兼首席执行官和董事会成员，并自2012年3月担任这些职位。2010年11月至2011年10月，他曾担任 Topaz Pharmaceuticals 的总裁和首席执行官。从2009年3月至2010年11月，从2008年12月至2009年3月担任Transmolecular的顾问后，他担任Transmolecular公司（生物技术公司，开发的癌症诊断和治疗产品）的总裁兼首席执行官。2008年9月至2008年12月他失业了。从2007年9月至2008年9月他担任Prestwick制药公司（一家专业制药公司）的首席商务官。加入 Prestwick之前，他担任一些制药和生物技术公司的中高层管理职位，包括Morphotek公司，Vicuron制药公司和礼来公司，并为Affinium制药有限公司的董事从2012年7月至2014年3月，此时大多数Affinium的资产被第三方收购了。他还担任Horse Power For Life的董事，2007年以来他就担任此职位。他获得波士顿学院化学学士学位。
- Robert S. Radie,has been a director since March 2020 and Chairman of the Board since April 2022. Mr. Radie has served as Chief Executive Officer and Chairman of the board of directors of Neuraptive Therapeutics, Inc., a private, clinical stage company focused on improving outcomes in traumatic peripheral nerve injury, since June 2020. He previously served as President and Chief Executive Officer and a member of the board of directors of Zyla Life Sciences, a life sciences company, from March 2012 to October 2019. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company. From March 2009 to November 2010, Mr. Radie served as President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company, after serving as a consultant to Transmolecular from December 2008 through March 2009. From September 2007 to September 2008, Mr. Radie served as the Chief Business Officer of Prestwick Pharmaceuticals, Inc., a specialty pharmaceutical company. Before joining Prestwick, Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie has been a member of the board of directors ValSource Inc. since October 2020 and has also served as a director of Orcosa Inc since Jan of 2024. He previously served as a member of the board of directors of Paratek Pharmaceuticals from November 2014 to September 2023,Veloxis Pharmaceuticals A/S from June 2016 to February 2020 and Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014. He also served as a Director for Life Science PA, an industry advocacy group in Pennsylvania. Previously, he served as a director of Horse Power for Life, a nonprofit organization of to improving the quality of life for individuals diagnosed with cancer from 2006 through 2024. Mr. Radie received his B.S. in Chemistry from Boston College.
高管简历
中英对照 | 中文 | 英文- Mark Strobeck
Mark Strobeck自2023年6月起担任Windtree Therapeutics, Inc.董事会成员，并担任审计和薪酬委员会成员。自2022年7月起，斯特罗贝克博士还担任生物制药公司Rockwell Medical, Inc.的总裁兼首席执行官和董事会成员。斯特罗贝克博士曾于2021年5月至2022年6月担任生命科学投资银行Aquilo Partners，LP的董事总经理。他曾于2020年5月至2020年12月担任制药公司Assertio Holdings, Inc.执行副总裁兼首席运营官。在此之前，斯特罗贝克博士于2015年9月与Assertio Holdings公司于2020年5月合并后担任制药公司Zyla Life Sciences的执行副总裁兼首席运营官，并曾于2014年1月至2015年9月担任Zyla的首席商务官。在受雇于Zyla之前，他曾在2012年6月至2013年12月期间担任Zyla的顾问。2012年1月至2013年12月，他担任Corridor Pharmaceuticals，Inc.的总裁兼首席执行官和董事。Corridor Pharmaceuticals，Inc.是一家制药公司，于2014年被阿斯利康收购。2010年12月至2011年10月，斯特罗贝克博士担任Topaz Pharmaceuticals Inc.的首席商务官，这是一家专业制药公司，于2011年第四季度被赛诺菲巴斯德收购。2010年6月至2010年11月和2011年10月至2012年1月，斯特罗贝克博士担任顾问。2008年1月至2010年5月，斯特罗贝克博士担任制药公司Trevena, Inc.的首席商务官。在加入Trevena之前，斯特罗贝克博士曾在制药公司葛兰素史克、风险投资公司SR One Limited和EuclidSR Partners，L.P担任管理职务。斯特罗贝克博士目前是Horse Power For Life的董事会成员，该公司是一家非营利组织，致力于提高被诊断患有癌症的人的生活质量，他自2012年以来一直担任该职位。斯特罗贝克博士于1993年在圣劳伦斯大学获得生物学学士学位，1999年在辛辛那提大学获得药理学和生物物理学博士学位，并于2001年在宾夕法尼亚大学医学院完成了心血管基因调控方面的博士后研究。
Mark Strobeck,has served as a member of Windtree Therapeutics, Inc. Board since June 2023 and also serves as a member of the Audit and Compensation Committees. Dr. Strobeck has also served as the President and CEO, and as a member of the board of directors, of Rockwell Medical, Inc., a biopharmaceutical company, since July 2022. Dr, Strobeck previously served as Managing Director of Aquilo Partners, LP, a life sciences investment bank, from May 2021 to June 2022. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company, from May 2020 to December 2020. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla's Chief Business Officer from January 2014 to September 2015. Before his employment at Zyla, he served as Zyla's advisor from June 2012 to December 2013. From January 2012 to December 2013, he served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University in 1993 and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati in 1999 and completed his post-doctoral fellowship in Cardiovascular Gene Regulation at the University of Pennsylvania School of Medicine in 2001.- Mark Strobeck自2023年6月起担任Windtree Therapeutics, Inc.董事会成员，并担任审计和薪酬委员会成员。自2022年7月起，斯特罗贝克博士还担任生物制药公司Rockwell Medical, Inc.的总裁兼首席执行官和董事会成员。斯特罗贝克博士曾于2021年5月至2022年6月担任生命科学投资银行Aquilo Partners，LP的董事总经理。他曾于2020年5月至2020年12月担任制药公司Assertio Holdings, Inc.执行副总裁兼首席运营官。在此之前，斯特罗贝克博士于2015年9月与Assertio Holdings公司于2020年5月合并后担任制药公司Zyla Life Sciences的执行副总裁兼首席运营官，并曾于2014年1月至2015年9月担任Zyla的首席商务官。在受雇于Zyla之前，他曾在2012年6月至2013年12月期间担任Zyla的顾问。2012年1月至2013年12月，他担任Corridor Pharmaceuticals，Inc.的总裁兼首席执行官和董事。Corridor Pharmaceuticals，Inc.是一家制药公司，于2014年被阿斯利康收购。2010年12月至2011年10月，斯特罗贝克博士担任Topaz Pharmaceuticals Inc.的首席商务官，这是一家专业制药公司，于2011年第四季度被赛诺菲巴斯德收购。2010年6月至2010年11月和2011年10月至2012年1月，斯特罗贝克博士担任顾问。2008年1月至2010年5月，斯特罗贝克博士担任制药公司Trevena, Inc.的首席商务官。在加入Trevena之前，斯特罗贝克博士曾在制药公司葛兰素史克、风险投资公司SR One Limited和EuclidSR Partners，L.P担任管理职务。斯特罗贝克博士目前是Horse Power For Life的董事会成员，该公司是一家非营利组织，致力于提高被诊断患有癌症的人的生活质量，他自2012年以来一直担任该职位。斯特罗贝克博士于1993年在圣劳伦斯大学获得生物学学士学位，1999年在辛辛那提大学获得药理学和生物物理学博士学位，并于2001年在宾夕法尼亚大学医学院完成了心血管基因调控方面的博士后研究。
- Mark Strobeck,has served as a member of Windtree Therapeutics, Inc. Board since June 2023 and also serves as a member of the Audit and Compensation Committees. Dr. Strobeck has also served as the President and CEO, and as a member of the board of directors, of Rockwell Medical, Inc., a biopharmaceutical company, since July 2022. Dr, Strobeck previously served as Managing Director of Aquilo Partners, LP, a life sciences investment bank, from May 2021 to June 2022. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company, from May 2020 to December 2020. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla's Chief Business Officer from January 2014 to September 2015. Before his employment at Zyla, he served as Zyla's advisor from June 2012 to December 2013. From January 2012 to December 2013, he served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. From December 2010 to October 2011, Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From June 2010 to November 2010 and October 2011 to January 2012, Dr. Strobeck worked as a consultant. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc., a pharmaceutical company. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P. Dr. Strobeck currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University in 1993 and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati in 1999 and completed his post-doctoral fellowship in Cardiovascular Gene Regulation at the University of Pennsylvania School of Medicine in 2001.
- Megan Timmins
Megan Timmins，自2022年9月起担任公司执行副总裁、首席法务官兼秘书，此前曾于2021年8月至2022年9月担任Rockwell Medical, Inc.高级副总裁、总法律顾问兼秘书。在此之前，她于2021年2月至2021年8月担任独立顾问，并于2020年5月至2021年1月担任商业制药公司Assertio Holdings, Inc.（ZYLA Life Sciences合并继任者）的高级副总裁、总法律顾问和秘书。2018年3月至2021年1月，她担任生命科学公司Zyla的高级副总裁兼总法律顾问，并于2018年6月至2021年1月担任Zyla的秘书。2017年9月至2018年3月，她担任Zyla副总裁兼代理总法律顾问。2016年10月至2018年8月，Timmins女士担任Zyla的副总法律顾问，2016年4月至2016年10月，她担任Zyla的顾问。在此之前，她曾在爱玛客担任越来越重要的职务，最近在2011年1月至2015年3月期间担任副总裁、协理总法律顾问和助理秘书。Timmins女士在圣母大学获得政府和经济学学士学位，在威廉和玛丽法学院获得法学博士学位。
Megan Timmins,has served as the Company's Executive Vice President, Chief Legal Officer and Secretary since September 2022 and previously served as Rockwell Medical, Inc. Senior Vice President, General Counsel and Secretary from August 2021 to September 2022. Prior to that, she was an independent consultant from February 2021 to August 2021 and from May 2020 to January 2021, she served as Senior Vice President, General Counsel and Secretary for Assertio Holdings, Inc. (successor by merger to Zyla Life Sciences), a commercial pharmaceutical company. From March 2018 to January 2021, she served as Senior Vice President and General Counsel of Zyla, a life sciences company, and as Zyla's Secretary from June 2018 to January 2021. From September 2017 to March 2018, she served as Zyla's Vice President and Acting General Counsel. From October 2016 to August 2018, Ms. Timmins served as Zyla's Deputy General Counsel and from April 2016 to October 2016, she served as a consultant at Zyla. Prior to that, she served in positions of increasing responsibility at Aramark, most recently as Vice President, Associate General Counsel and Assistant Secretary from January 2011 until March 2015. Ms. Timmins received her B.A. in Government and Economics from the University of Notre Dame and her J.D. from the William and Mary Law School.- Megan Timmins，自2022年9月起担任公司执行副总裁、首席法务官兼秘书，此前曾于2021年8月至2022年9月担任Rockwell Medical, Inc.高级副总裁、总法律顾问兼秘书。在此之前，她于2021年2月至2021年8月担任独立顾问，并于2020年5月至2021年1月担任商业制药公司Assertio Holdings, Inc.（ZYLA Life Sciences合并继任者）的高级副总裁、总法律顾问和秘书。2018年3月至2021年1月，她担任生命科学公司Zyla的高级副总裁兼总法律顾问，并于2018年6月至2021年1月担任Zyla的秘书。2017年9月至2018年3月，她担任Zyla副总裁兼代理总法律顾问。2016年10月至2018年8月，Timmins女士担任Zyla的副总法律顾问，2016年4月至2016年10月，她担任Zyla的顾问。在此之前，她曾在爱玛客担任越来越重要的职务，最近在2011年1月至2015年3月期间担任副总裁、协理总法律顾问和助理秘书。Timmins女士在圣母大学获得政府和经济学学士学位，在威廉和玛丽法学院获得法学博士学位。
- Megan Timmins,has served as the Company's Executive Vice President, Chief Legal Officer and Secretary since September 2022 and previously served as Rockwell Medical, Inc. Senior Vice President, General Counsel and Secretary from August 2021 to September 2022. Prior to that, she was an independent consultant from February 2021 to August 2021 and from May 2020 to January 2021, she served as Senior Vice President, General Counsel and Secretary for Assertio Holdings, Inc. (successor by merger to Zyla Life Sciences), a commercial pharmaceutical company. From March 2018 to January 2021, she served as Senior Vice President and General Counsel of Zyla, a life sciences company, and as Zyla's Secretary from June 2018 to January 2021. From September 2017 to March 2018, she served as Zyla's Vice President and Acting General Counsel. From October 2016 to August 2018, Ms. Timmins served as Zyla's Deputy General Counsel and from April 2016 to October 2016, she served as a consultant at Zyla. Prior to that, she served in positions of increasing responsibility at Aramark, most recently as Vice President, Associate General Counsel and Assistant Secretary from January 2011 until March 2015. Ms. Timmins received her B.A. in Government and Economics from the University of Notre Dame and her J.D. from the William and Mary Law School.
- Jesse Neri
Jesse Neri，自2024年12月起担任首席财务官，自2023年10月起担任财务高级副总裁。在加入公司之前，Neri先生于2021年8月至2023年10月担任Hemavant Sciences和Aruvant Sciences的财务执行董事，这两家临床阶段的生物制药公司是Roivant投资组合的成员。从2020年5月到2021年8月，Neri先生是一名自营顾问。Neri先生于2020年1月至2020年5月担任制药公司Zyla Life Sciences的财务高级副总裁，于2019年3月至2020年1月担任Zyla的财务副总裁，在此之前，担任财务规划和分析执行董事，在此之前，担任财务规划和分析高级总监。在加入Zyla之前，Neri先生曾在Symphony Health Solutions担任财务规划和分析副总裁。他的职业生涯始于Ellucian，这是一家领先的高等教育机构ERP软件提供商，在那里他担任了各种越来越重要的角色。Neri先生获得维拉诺瓦大学金融工商管理学士学位和德雷塞尔大学勒鲍商学院工商管理硕士学位。
Jesse Neri,has been Chief Financial Officer since December 2024 and Senior Vice President, Finance, since October 2023. Prior to joining the Company, Mr. Neri was the Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, clinical-stage biopharmaceutical companies that are members of the Roivant portfolio, from August 2021 to October 2023. From May 2020 to August 2021, Mr. Neri was a self-employed consultant. Mr. Neri served as Senior Vice President of Finance at Zyla Life Sciences, a pharmaceutical company, from January 2020 to May 2020, as Vice President of Finance of Zyla from March 2019 to January 2020 and prior to that, as Executive Director, Financial Planning and Analysis and prior to that, as Senior Director of Financial Planning and Analysis. Prior to Zyla, Mr. Neri served as Vice President of Financial Planning and Analysis at Symphony Health Solutions. He started his career at Ellucian, a leading ERP software provider for higher education institutions, where he held various roles of increasing responsibility. Mr. Neri received a B.S., Business Administration of Finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business.- Jesse Neri，自2024年12月起担任首席财务官，自2023年10月起担任财务高级副总裁。在加入公司之前，Neri先生于2021年8月至2023年10月担任Hemavant Sciences和Aruvant Sciences的财务执行董事，这两家临床阶段的生物制药公司是Roivant投资组合的成员。从2020年5月到2021年8月，Neri先生是一名自营顾问。Neri先生于2020年1月至2020年5月担任制药公司Zyla Life Sciences的财务高级副总裁，于2019年3月至2020年1月担任Zyla的财务副总裁，在此之前，担任财务规划和分析执行董事，在此之前，担任财务规划和分析高级总监。在加入Zyla之前，Neri先生曾在Symphony Health Solutions担任财务规划和分析副总裁。他的职业生涯始于Ellucian，这是一家领先的高等教育机构ERP软件提供商，在那里他担任了各种越来越重要的角色。Neri先生获得维拉诺瓦大学金融工商管理学士学位和德雷塞尔大学勒鲍商学院工商管理硕士学位。
- Jesse Neri,has been Chief Financial Officer since December 2024 and Senior Vice President, Finance, since October 2023. Prior to joining the Company, Mr. Neri was the Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, clinical-stage biopharmaceutical companies that are members of the Roivant portfolio, from August 2021 to October 2023. From May 2020 to August 2021, Mr. Neri was a self-employed consultant. Mr. Neri served as Senior Vice President of Finance at Zyla Life Sciences, a pharmaceutical company, from January 2020 to May 2020, as Vice President of Finance of Zyla from March 2019 to January 2020 and prior to that, as Executive Director, Financial Planning and Analysis and prior to that, as Senior Director of Financial Planning and Analysis. Prior to Zyla, Mr. Neri served as Vice President of Financial Planning and Analysis at Symphony Health Solutions. He started his career at Ellucian, a leading ERP software provider for higher education institutions, where he held various roles of increasing responsibility. Mr. Neri received a B.S., Business Administration of Finance from Villanova University and an M.B.A. from Drexel University LeBow School of Business.
- Timothy Chole
Timothy Chole，自2024年5月起担任高级副总裁兼首席商务官。他于2021年2月至2024年5月担任销售和市场营销高级副总裁，并于2019年12月至2021年2月担任市场营销副总裁Rockwell Medical, Inc.。在加入公司之前，Chole先生于2016年11月至2019年7月在Cochlear Americas担任听力植入产品营销和专业教育总监。在此之前，他曾在百特国际公司担任职责不断增加的职位，最近担任Integrated Pharmacy Automation全球营销总监。在其职业生涯的早期，Chole先生曾在Watson Pharmaceuticals（现为Allergan）担任IV铁组合的营销主管，后来在Gambro AB（现为百特国际有限公司）担任AKI疗法的全球营销总监。他的背景包括全球和美国销售、营销领导和市场开发角色。Chole先生获得了加州大学戴维斯分校管理经济学理学学士学位。
Timothy Chole,has been Senior Vice President and Chief Commercial Officer since May 2024. He served as Senior Vice President, Sales and Marketing, from February 2021 to May 2024 and as Rockwell Medical, Inc. Vice President of Marketing from December 2019 to February 2021. Prior to joining the Company, Mr. Chole served as the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas from November 2016 to July 2019. Prior to that, he served in positions of increasing responsibility at Baxter International, Inc., most recently as the Global Marketing Director for Integrated Pharmacy Automation. Early in his career, Mr. Chole served as the marketing lead for the IV iron portfolio at Watson Pharmaceuticals (now Allergan), and later was the Global Marketing Director for AKI Therapy at Gambro AB (now Baxter International Inc.). His background includes global and U.S. sales, marketing leadership and market development roles. Mr. Chole received a Bachelor of Science degree in managerial economics from the University of California at Davis.- Timothy Chole，自2024年5月起担任高级副总裁兼首席商务官。他于2021年2月至2024年5月担任销售和市场营销高级副总裁，并于2019年12月至2021年2月担任市场营销副总裁Rockwell Medical, Inc.。在加入公司之前，Chole先生于2016年11月至2019年7月在Cochlear Americas担任听力植入产品营销和专业教育总监。在此之前，他曾在百特国际公司担任职责不断增加的职位，最近担任Integrated Pharmacy Automation全球营销总监。在其职业生涯的早期，Chole先生曾在Watson Pharmaceuticals（现为Allergan）担任IV铁组合的营销主管，后来在Gambro AB（现为百特国际有限公司）担任AKI疗法的全球营销总监。他的背景包括全球和美国销售、营销领导和市场开发角色。Chole先生获得了加州大学戴维斯分校管理经济学理学学士学位。
- Timothy Chole,has been Senior Vice President and Chief Commercial Officer since May 2024. He served as Senior Vice President, Sales and Marketing, from February 2021 to May 2024 and as Rockwell Medical, Inc. Vice President of Marketing from December 2019 to February 2021. Prior to joining the Company, Mr. Chole served as the Director of Product Marketing and Professional Education for hearing implants at Cochlear Americas from November 2016 to July 2019. Prior to that, he served in positions of increasing responsibility at Baxter International, Inc., most recently as the Global Marketing Director for Integrated Pharmacy Automation. Early in his career, Mr. Chole served as the marketing lead for the IV iron portfolio at Watson Pharmaceuticals (now Allergan), and later was the Global Marketing Director for AKI Therapy at Gambro AB (now Baxter International Inc.). His background includes global and U.S. sales, marketing leadership and market development roles. Mr. Chole received a Bachelor of Science degree in managerial economics from the University of California at Davis.
- Heather Hunter
Heather Hunter，最近自2022年8月起担任公司高级副总裁兼首席公司事务官，并于2022年7月至2022年8月担任独立顾问。在加入公司之前，Hunter女士于2018年1月至2022年8月在Venatorx Pharmaceuticals担任传播和公司事务副总裁，该公司是一家私营的、风险投资支持的、商业化前的制药公司，专注于抗菌和抗病毒药物的研发。在此之前，Hunter女士曾在安科投资（NYSE：SFE）担任越来越重要的职务，这是一家小型风险投资公司，投资于早期和成长阶段的医疗保健和技术公司，最近一次担任营销和传播副总裁，时间为2006年10月至2018年1月；W.P. Carey（NYSE：WPC），最近一次担任企业传播副总裁，时间为2000年9月至2006年10月。亨特女士目前担任Journal My Health的顾问委员会成员，Journal My Health是一家专注于慢性病患者的数字健康平台，并且是Golden Seeds的董事总经理，Golden Seeds是一家天使投资公司，投资于女性领导和女性创立的公司。亨特女士毕业于耶鲁大学，获得历史学学士学位。
Heather Hunter,most recently served as the Company's Senior Vice President and Chief Corporate Affairs Officer since August 2022 and an independent consultant from July 2022 through August 2022. Prior to joining the Company, Ms. Hunter served as Vice President, Communications and Corporate Affairs at Venatorx Pharmaceuticals, a private, venture-backed, pre-commercial pharmaceutical company focused on antibacterial and antiviral drug research and development, from January 2018 to August 2022. Prior to that, Ms. Hunter served in positions of increasing responsibility at Safeguard Scientifics (NYSE:SFE), a small-cap venture capital firm that invested in early- and growth-stage healthcare and technology companies, most recently as Vice President, Marketing and Communications, from October 2006 to January 2018, and W.P. Carey (NYSE:WPC), most recently as Vice President, Corporate Communications, from September 2000 to October 2006. Ms. Hunter currently serves as an Advisory Board member of Journal Rockwell Medical, Inc.'s Health, a digital health platform focused on patients with chronic conditions, and is a Managing Director at Golden Seeds, an angel investment firm that invests in women-led and women-founded companies. Ms. Hunter graduated with a B.A. in History from Yale University.- Heather Hunter，最近自2022年8月起担任公司高级副总裁兼首席公司事务官，并于2022年7月至2022年8月担任独立顾问。在加入公司之前，Hunter女士于2018年1月至2022年8月在Venatorx Pharmaceuticals担任传播和公司事务副总裁，该公司是一家私营的、风险投资支持的、商业化前的制药公司，专注于抗菌和抗病毒药物的研发。在此之前，Hunter女士曾在安科投资（NYSE：SFE）担任越来越重要的职务，这是一家小型风险投资公司，投资于早期和成长阶段的医疗保健和技术公司，最近一次担任营销和传播副总裁，时间为2006年10月至2018年1月；W.P. Carey（NYSE：WPC），最近一次担任企业传播副总裁，时间为2000年9月至2006年10月。亨特女士目前担任Journal My Health的顾问委员会成员，Journal My Health是一家专注于慢性病患者的数字健康平台，并且是Golden Seeds的董事总经理，Golden Seeds是一家天使投资公司，投资于女性领导和女性创立的公司。亨特女士毕业于耶鲁大学，获得历史学学士学位。
- Heather Hunter,most recently served as the Company's Senior Vice President and Chief Corporate Affairs Officer since August 2022 and an independent consultant from July 2022 through August 2022. Prior to joining the Company, Ms. Hunter served as Vice President, Communications and Corporate Affairs at Venatorx Pharmaceuticals, a private, venture-backed, pre-commercial pharmaceutical company focused on antibacterial and antiviral drug research and development, from January 2018 to August 2022. Prior to that, Ms. Hunter served in positions of increasing responsibility at Safeguard Scientifics (NYSE:SFE), a small-cap venture capital firm that invested in early- and growth-stage healthcare and technology companies, most recently as Vice President, Marketing and Communications, from October 2006 to January 2018, and W.P. Carey (NYSE:WPC), most recently as Vice President, Corporate Communications, from September 2000 to October 2006. Ms. Hunter currently serves as an Advisory Board member of Journal Rockwell Medical, Inc.'s Health, a digital health platform focused on patients with chronic conditions, and is a Managing Director at Golden Seeds, an angel investment firm that invests in women-led and women-founded companies. Ms. Hunter graduated with a B.A. in History from Yale University.